• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Gilead Cancer Drug Deal Might Change The Case For Investing In Vir Biotechnology (VIR)

    Simply Wall St·10/20/2026 11:33:00
    Listen to the news
    • Vir Biotechnology announced a collaboration and license agreement with Gilead that gives Gilead exclusive rights to develop and commercialize up to three PRO-XTEN dual-masked T-cell engagers for solid tumors, with Vir handling early discovery and design and receiving a mix of cash, equity and milestone-based payments.
    • The deal brings Vir Biotechnology up to $135 million in upfront and near-term milestones plus potential longer term payments and royalties, which directly ties its PRO-XTEN oncology platform to a large partner and helps fund clinical programs without relying solely on its own balance sheet.
    • We will now look at how Vir Biotechnology's Gilead funded T-cell engager collaboration could influence the investment narrative around its oncology expansion.

    Scan Vir Biotechnology's oncology pivot against a curated field of peers by reviewing our 33 healthcare AI stocks that are also pushing the boundaries of immuno-oncology and targeted therapies.

    Vir Biotechnology Investment Narrative Recap

    To own Vir Biotechnology, you need to believe its infectious disease base and PRO-XTEN oncology platform can support a long runway of partnered assets, even with current losses and forecast earnings pressure. The Gilead tie-up brings cash, equity and milestones that can help fund this shift without leaning entirely on new equity raises.

    In the near term, ECLIPSE in hepatitis delta and early oncology readouts remain key swing factors for sentiment. The Gilead agreement appears helpful for funding and validation; however, it does not remove the core risk that unproven T-cell engagers and other programs may produce uneven clinical outcomes and prolonged unprofitability.

    The FDA Fast Track designation for VIR-5500 is tightly linked to this story. It shows regulators are engaging with Vir Biotechnology's first PRO-XTEN T-cell engager in prostate cancer and that the platform is already in human studies, with a Phase 1 trial under way across several mCRPC and mHSPC cohorts.

    If VIR-5500 continues to show acceptable safety and early anti-tumor activity, that readthrough could matter for the newer Gilead-partnered solid tumor T-cell engagers. Any setback for VIR-5500, whether clinical or regulatory, would likely weigh on confidence in PRO-XTEN as a growth pillar and increase focus on Vir's cash burn and dependence on partners.

    Vir Biotechnology's setup assumes revenue of US$171.2 million and earnings of US$32.5 million by 2029. That profile is based on analysts modelling 37.8% yearly revenue growth and an earnings swing of about US$475.2 million from a current loss of US$442.7 million.

    Uncover why Vir Biotechnology's fair value indicates a 111% potential upside to its current price that could narrow quickly.

    NasdaqGS:VIR 1-Year Stock Price Chart
    NasdaqGS:VIR 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts frame Vir Biotechnology very differently. They lean into the hepatitis delta opportunity and, even before this Gilead news, were modelling revenue of about US$355.8 million and earnings of roughly US$57.8 million by 2029. That is a far richer story than consensus. It could also shift again as you weigh fresh information.

    Explore another Vir Biotechnology fair value estimate, including one that suggests as much as 111% upside from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Vir Biotechnology research is our analysis highlighting 3 important warning signs that could impact your investment decision.
    • See our latest analysis for Vir Biotechnology. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Vir Biotechnology's overall financial health at a glance.

    Looking For More Investment Ideas Beyond Vir Biotechnology?

    If the Vir Biotechnology story has sharpened your thinking but you want a broader hunting ground, the Simply Wall St Screener can help you surface other opportunities that fit your style and risk appetite.